CoChat

Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Impaired activated protein C (aPC) generation is associated with atherosclerosis and diabetes mellitus. Diabetes-associated atherosclerosis is characterized by the hyperglycaemic memory, e.g., failure of disease improvement despite attenuation of hyperglycaemia. Therapies reversing the hyperglycaemic memory are lacking. Here we demonstrate that hyperglycaemia, but not hyperlipidaemia, induces the redox-regulator p66 Shc and reactive oxygen species (ROS) in macrophages. p66 Shc expression, ROS generation, and a pro-atherogenic phenotype are sustained despite restoring normoglycemic conditions. Inhibition of p66 Shc abolishes this sustained pro-atherogenic phenotype, identifying p66 Shc -dependent ROS in macrophages as a key mechanism conveying the hyperglycaemic memory. The p66 Shc -associated hyperglycaemic memory can be reversed by aPC via protease-activated receptor-1 signalling. aPC reverses glucose-induced CpG hypomethylation within the p66 Shc promoter by induction of the DNA methyltransferase-1 (DNMT1). Thus, epigenetically sustained p66 Shc expression in plaque macrophages drives the hyperglycaemic memory, which—however—can be reversed by aPC. This establishes that reversal of the hyperglycaemic memory in diabetic atherosclerosis is feasible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-018-0108-5

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Plaques are less stable in hyperglycaemic versus hyperlipidaemic ApoE-deficient mice. a Representative images of thoracic aortae showing en face plaques as detected by Oil Red O staining (left panel) and dot plot summarizing data (total area stained with Oil Red O, right panel) in control (normal chow diet, Cont), hyperlipidaemic (high-fat diet, HFD), and diabetic (STZ-induced hyperglycaemia, DM) mice. b–g Representative images showing MOVATs staining (b, upper panel) and Oil Red O staining of brachiocephalic arteries (b, middle panel) and aortic roots (b, lower panel). Morphometric analyses of MOVATs and Oil Red O-stained images reveal smaller plaques (c, d), but increased necrotic core area (e), thinner fibrous caps (f), and more ruptured shoulders (g) in ApoE−/− DM mice compared to ApoE−/− HFD. Dot plots in e–g summarize results obtained from MOVAT-stained brachiocephalic arteries (b, top). Necrotic core area within plaque is indicated by b *, fibrous caps thickness by a black arrow, and ruptured shoulders by a red arrow (b). h Representative images showing immunofluorescence staining of macrophages (upper panel, MOMA-2, green; DAPI nuclear counterstain, blue) and smooth muscle cells (lower panel, α-actin, positive cells detected by HRP-DAB reaction, brown) within lesions and dot plot summarizing data. Cont: non-diabetic ApoE−/− mice receiving normal chow diet; HFD: ApoE−/− mice receiving high-fat diet (HFD); DM: hyperglycaemic ApoE−/− mice. Data shown as dot plots represent mean ± SEM of 10–12 mice per group (a, c–h); size bars: b, h: 20 µm; *P < 0.05, **P < 0.01; a, c, d: one-way ANOVA with Bonferroni-adjusted post hoc comparison of HFD and DM versus Cont and HFD versus DM; e–h t-test
Fig. 1 Plaques are less stable in hyperglycaemic versus hyperlipidaemic ApoE-deficient mice. a Representative images of thoracic aortae showing en face plaques as detected by Oil Red O staining (left panel) and dot plot summarizing data (total area stained with Oil Red O, right panel) in control (normal chow diet, Cont), hyperlipidaemic (high-fat diet, HFD), and diabetic (STZ-induced hyperglycaemia, DM) mice. b–g Representative images showing MOVATs staining (b, upper panel) and Oil Red O staining of brachiocephalic arteries (b, middle panel) and aortic roots (b, lower panel). Morphometric analyses of MOVATs and Oil Red O-stained images reveal smaller plaques (c, d), but increased necrotic core area (e), thinner fibrous caps (f), and more ruptured shoulders (g) in ApoE−/− DM mice compared to ApoE−/− HFD. Dot plots in e–g summarize results obtained from MOVAT-stained brachiocephalic arteries (b, top). Necrotic core area within plaque is indicated by b *, fibrous caps thickness by a black arrow, and ruptured shoulders by a red arrow (b). h Representative images showing immunofluorescence staining of macrophages (upper panel, MOMA-2, green; DAPI nuclear counterstain, blue) and smooth muscle cells (lower panel, α-actin, positive cells detected by HRP-DAB reaction, brown) within lesions and dot plot summarizing data. Cont: non-diabetic ApoE−/− mice receiving normal chow diet; HFD: ApoE−/− mice receiving high-fat diet (HFD); DM: hyperglycaemic ApoE−/− mice. Data shown as dot plots represent mean ± SEM of 10–12 mice per group (a, c–h); size bars: b, h: 20 µm; *P < 0.05, **P < 0.01; a, c, d: one-way ANOVA with Bonferroni-adjusted post hoc comparison of HFD and DM versus Cont and HFD versus DM; e–h t-testCC BY · PubMed Central
Fig. 2 p66Shc and CD36 expressions are increased in plaque-associated macrophages in diabetic mice. a, b Representative reverse-transcriptase-PCR gel images showing expression of CD68, p66Shc, CD36, β-actin (loading control), and SMCα-actin (reflecting purity of laser-dissected macrophages, a, left panel) and dot plot summarizing data for CD36 (a, middle panel) and p66Shc (a, right panel). Representative images showing co-immunofluorescence staining for p66Shc (red), MOMA-2 (green), and DAPI nuclear counterstain (blue) within lesions of the brachiocephalic artery (b, left panel) and dot plot summarizing data using automated digital co-localization analyses, yielding a correlation index (Icorr) (b, right panel). c Representative immunoblot images of CD36 (out of 4 independent repeat experiments with two technical replicates each, top) and dot plot summarizing data (bottom) in ApoE−/− and ApoE−/− p66Shc−/− bone marrow-derived macrophages (BMDMs); NG normal glucose (5 mM), HG high glucose (25 mM), GAPDH: loading control. d Representative co-immunofluorescence images for CD36 (red), MOMA-2 (green), DAPI nuclear counterstain (blue) within lesions of the brachiocephalic artery in ApoE−/− HFD and ApoE−/− DM mice (left panel) and dot plot summarising data (Icorr, correlation index, right panel). DM: hyperglycemic ApoE−/− mice; HFD: ApoE−/− mice with high-fat diet (HFD). Data shown as dot plots represent mean ± SEM of 10 mice per group (a, b, d) or 4 biological distinct replicates (c); size bars: b, d: 20 µm; **P < 0.01; a, b, d: t-test; c: two-way ANOVA with Bonferroni-adjusted post hoc comparison of ApoE−/− (NG, HG) versus p66Shc−/− ApoE−/− (NG, HG, respectively) BMDMs. Uncropped reverse-transcriptase PCR gel images for Fig. 2a and immunoblots for Fig. 2c are provided in Supplementary Figure 19
Fig. 2 p66Shc and CD36 expressions are increased in plaque-associated macrophages in diabetic mice. a, b Representative reverse-transcriptase-PCR gel images showing expression of CD68, p66Shc, CD36, β-actin (loading control), and SMCα-actin (reflecting purity of laser-dissected macrophages, a, left panel) and dot plot summarizing data for CD36 (a, middle panel) and p66Shc (a, right panel). Representative images showing co-immunofluorescence staining for p66Shc (red), MOMA-2 (green), and DAPI nuclear counterstain (blue) within lesions of the brachiocephalic artery (b, left panel) and dot plot summarizing data using automated digital co-localization analyses, yielding a correlation index (Icorr) (b, right panel). c Representative immunoblot images of CD36 (out of 4 independent repeat experiments with two technical replicates each, top) and dot plot summarizing data (bottom) in ApoE−/− and ApoE−/− p66Shc−/− bone marrow-derived macrophages (BMDMs); NG normal glucose (5 mM), HG high glucose (25 mM), GAPDH: loading control. d Representative co-immunofluorescence images for CD36 (red), MOMA-2 (green), DAPI nuclear counterstain (blue) within lesions of the brachiocephalic artery in ApoE−/− HFD and ApoE−/− DM mice (left panel) and dot plot summarising data (Icorr, correlation index, right panel). DM: hyperglycemic ApoE−/− mice; HFD: ApoE−/− mice with high-fat diet (HFD). Data shown as dot plots represent mean ± SEM of 10 mice per group (a, b, d) or 4 biological distinct replicates (c); size bars: b, d: 20 µm; **P < 0.01; a, b, d: t-test; c: two-way ANOVA with Bonferroni-adjusted post hoc comparison of ApoE−/− (NG, HG) versus p66Shc−/− ApoE−/− (NG, HG, respectively) BMDMs. Uncropped reverse-transcriptase PCR gel images for Fig. 2a and immunoblots for Fig. 2c are provided in Supplementary Figure 19CC BY · PubMed Central
Fig. 3 p66Shc and CD36 expressions are increased in plaque-associated macrophages in diabetic patients. Representative co-immunofluorescence images for p66Shc (red, a, left panel), CD36 (red, b, left panel), MOMA-2 (green, a, b, left panels), and DAPI nuclear counterstain (blue) and dot plot summarising data (Icorr; correlation index, right panels). Co-localization of p66Shc and CD36 with the macrophage marker MOMA-2 is increased in diabetic patient’s samples (N = 10) as compared to non-diabetic patient’s samples (N = 10). DM: diabetic patient’s samples; non-DM: non-diabetic patient’s samples. Data shown as dot plots represent mean ± SEM of 10 patients per group, size bars: 20 µm; **P < 0.01; a Mann–Whitney U test, b t-test
Fig. 3 p66Shc and CD36 expressions are increased in plaque-associated macrophages in diabetic patients. Representative co-immunofluorescence images for p66Shc (red, a, left panel), CD36 (red, b, left panel), MOMA-2 (green, a, b, left panels), and DAPI nuclear counterstain (blue) and dot plot summarising data (Icorr; correlation index, right panels). Co-localization of p66Shc and CD36 with the macrophage marker MOMA-2 is increased in diabetic patient’s samples (N = 10) as compared to non-diabetic patient’s samples (N = 10). DM: diabetic patient’s samples; non-DM: non-diabetic patient’s samples. Data shown as dot plots represent mean ± SEM of 10 patients per group, size bars: 20 µm; **P < 0.01; a Mann–Whitney U test, b t-testCC BY · PubMed Central
Fig. 4 p66Shc has a pivotal function in hyperglycaemia-, but not hyperlipidaemia-induced atherosclerosis. a. Experimental design of bone marrow transplantation experiments. b. Transplantation of p66Shc−/− deficient bone marrow markedly reduces hyperglycaemia-, but only slightly hyperlipidaemia-induced atherosclerosis. Representative images showing Oil Red O staining of aortic roots (left panel) and dot plot summarizing plaques size (right panel). c. Dot plots summarizing results of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d. Representative images showing immunofluorescence staining of macrophages (MOMA-2, green; DAPI nuclear counterstain, blue) within lesions (left panel) and dot plot summarizing data (right panel). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM: hyperglycaemic ApoE−/− mice; HFD: ApoE−/− mice with high-fat diet (HFD). Data shown as dot plots represent mean ± SEM of 6–10 mice per group (b–d); size bars: b, d: 20 µm; **P < 0.01; b–d: two-way ANOVA with Bonferroni-adjusted post hoc comparison of ApoE−/− (Cont, HFD, DM) versus p66Shc−/− ApoE−/− (Cont, HFD, DM respectively) recipient mice
Fig. 4 p66Shc has a pivotal function in hyperglycaemia-, but not hyperlipidaemia-induced atherosclerosis. a. Experimental design of bone marrow transplantation experiments. b. Transplantation of p66Shc−/− deficient bone marrow markedly reduces hyperglycaemia-, but only slightly hyperlipidaemia-induced atherosclerosis. Representative images showing Oil Red O staining of aortic roots (left panel) and dot plot summarizing plaques size (right panel). c. Dot plots summarizing results of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d. Representative images showing immunofluorescence staining of macrophages (MOMA-2, green; DAPI nuclear counterstain, blue) within lesions (left panel) and dot plot summarizing data (right panel). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM: hyperglycaemic ApoE−/− mice; HFD: ApoE−/− mice with high-fat diet (HFD). Data shown as dot plots represent mean ± SEM of 6–10 mice per group (b–d); size bars: b, d: 20 µm; **P < 0.01; b–d: two-way ANOVA with Bonferroni-adjusted post hoc comparison of ApoE−/− (Cont, HFD, DM) versus p66Shc−/− ApoE−/− (Cont, HFD, DM respectively) recipient miceCC BY · PubMed Central
Fig. 5 In vivo silencing of p66Shc by vivo morpholino reduces hyperglycaemia-induced atherosclerosis. a Experimental design of vivo morpholino p66Shc silencing experiments. b Representative images of Oil Red-O staining of the aortic root lesions (left panel) and dot plot summarizing plaque size (right panel). c Dot plots summarizing result of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d Representative images showing immunofluorescence staining of macrophages (MOMA-2, green; DAPI nuclear counterstain, blue) within lesions (left panel) and dot plot summarizing data (right panel). Cont: normoglycaemic control mice; DM: hyperglycaemic ApoE−/− mice treated with PBS; Cont-MO: hyperglycaemic ApoE−/− mice treated with control vivo morpholino; p66Shc-MO: hyperglycaemic ApoE−/− mice treated with p66Shc-specific vivo morpholino. Data shown as dot plots represent mean ± SEM of 6–10 mice per group (b–d); size bars: b, d 20 µm; **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM and DM-Cont-MO versus Cont and DM-p66Shc-MO versus DM-Cont-MO (b, d) or DM-p66Shc-MO versus DM-Cont-MO and DM (c)
Fig. 5 In vivo silencing of p66Shc by vivo morpholino reduces hyperglycaemia-induced atherosclerosis. a Experimental design of vivo morpholino p66Shc silencing experiments. b Representative images of Oil Red-O staining of the aortic root lesions (left panel) and dot plot summarizing plaque size (right panel). c Dot plots summarizing result of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d Representative images showing immunofluorescence staining of macrophages (MOMA-2, green; DAPI nuclear counterstain, blue) within lesions (left panel) and dot plot summarizing data (right panel). Cont: normoglycaemic control mice; DM: hyperglycaemic ApoE−/− mice treated with PBS; Cont-MO: hyperglycaemic ApoE−/− mice treated with control vivo morpholino; p66Shc-MO: hyperglycaemic ApoE−/− mice treated with p66Shc-specific vivo morpholino. Data shown as dot plots represent mean ± SEM of 6–10 mice per group (b–d); size bars: b, d 20 µm; **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM and DM-Cont-MO versus Cont and DM-p66Shc-MO versus DM-Cont-MO (b, d) or DM-p66Shc-MO versus DM-Cont-MO and DM (c)CC BY · PubMed Central
Fig. 6 aPC reverses glucose-induced sustained p66Shc expression and the pro-atherogenic phenotype of macrophages. a, b Representative immunoblot images (out of four independent repeat experiments with two technical replicates each, left) and dot plot summarizing relative expression levels (right panels) of p66Shc, CD36, and GAPDH (loading control) in mouse bone marrow-derived macrophages (BMDMs) exposed to different lipid (a) or glucose (b) concentrations without or with additional aPC treatment. c Representative immunoblot images (out of 6 independent repeat experiments with two technical replicates each, top) and dot plot summarizing data (bottom) of p66Shc and GAPDH (loading control) in BMDMs isolated from non-hyperglycaemic (control, Cont), hyperglycaemic (DM, 22 weeks persistent hyperglycaemia), transiently hyperglycaemic (DM-NG, 16 weeks of sustained hyperglycaemia followed by 6 weeks of SGLT2-inhbitor treatment), or DM-NG-aPC (DM-NG mice with aPC treatment parallel to SGLT2-inhibitors treatment). d Representative immunoblot images of p66Shc (out of four independent repeat experiments with two technical replicates each) and GAPDH (loading control) in wild-type (WT), PAR1−/−, PAR2−/−, or PAR3−/− BMDMs (d, left panel) and in WT-BMDMs exposed to inhibitory antibodies of PAR4 or EPCR (d, right panels). NL: normal LDL; HL: high LDL (50 µg/ml, 48 h); HL-NL: 50 µg/ml LDL, 48 h, followed by NL, 24 h); NG: normal glucose (5 mM glucose plus 20 mM mannitol, NG, 48 h); HG: high glucose (25 mM, 48 h); HG-NG: high glucose followed by normal glucose (25 mM glucose, 48 h, followed by 5 mM glucose, 24 h), HG-NG-aPC: HG-NG treated in addition with aPC (20 nM for the last 24 h); Data shown as dot plots represent mean ± SEM of at least 3 independent repeat experiments with at least two technical replicates each; **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of HL versus NL and HL-NL versus HL (a), HG and HG-NG versus NG and HG-NG-aPC versus HG-NG (b, d), DM and DM-NG versus Cont and DM-NG-aPC versus DM-NG (c), HG-NG-aPC (αPAR4 and αEPCR-4 BMDMs) versus HG-NG-aPC (d, right panel) BMDMs. One-way ANOVA with Bonferroni-adjusted post hoc comparison of WT (HG and HG-NG versus NG and HG-NG-aPC versus HG-NG) and HG-NG-aPC (PAR3−/− and PAR2−/− BMDMs) versus HG-NG-aPC (PAR1−/− BMDMs) (d, left panel). Uncropped immunoblots for Fig. 6a–d are provided in Supplementary Figure 20 and Supplementary Figure 21, respectively
Fig. 6 aPC reverses glucose-induced sustained p66Shc expression and the pro-atherogenic phenotype of macrophages. a, b Representative immunoblot images (out of four independent repeat experiments with two technical replicates each, left) and dot plot summarizing relative expression levels (right panels) of p66Shc, CD36, and GAPDH (loading control) in mouse bone marrow-derived macrophages (BMDMs) exposed to different lipid (a) or glucose (b) concentrations without or with additional aPC treatment. c Representative immunoblot images (out of 6 independent repeat experiments with two technical replicates each, top) and dot plot summarizing data (bottom) of p66Shc and GAPDH (loading control) in BMDMs isolated from non-hyperglycaemic (control, Cont), hyperglycaemic (DM, 22 weeks persistent hyperglycaemia), transiently hyperglycaemic (DM-NG, 16 weeks of sustained hyperglycaemia followed by 6 weeks of SGLT2-inhbitor treatment), or DM-NG-aPC (DM-NG mice with aPC treatment parallel to SGLT2-inhibitors treatment). d Representative immunoblot images of p66Shc (out of four independent repeat experiments with two technical replicates each) and GAPDH (loading control) in wild-type (WT), PAR1−/−, PAR2−/−, or PAR3−/− BMDMs (d, left panel) and in WT-BMDMs exposed to inhibitory antibodies of PAR4 or EPCR (d, right panels). NL: normal LDL; HL: high LDL (50 µg/ml, 48 h); HL-NL: 50 µg/ml LDL, 48 h, followed by NL, 24 h); NG: normal glucose (5 mM glucose plus 20 mM mannitol, NG, 48 h); HG: high glucose (25 mM, 48 h); HG-NG: high glucose followed by normal glucose (25 mM glucose, 48 h, followed by 5 mM glucose, 24 h), HG-NG-aPC: HG-NG treated in addition with aPC (20 nM for the last 24 h); Data shown as dot plots represent mean ± SEM of at least 3 independent repeat experiments with at least two technical replicates each; **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of HL versus NL and HL-NL versus HL (a), HG and HG-NG versus NG and HG-NG-aPC versus HG-NG (b, d), DM and DM-NG versus Cont and DM-NG-aPC versus DM-NG (c), HG-NG-aPC (αPAR4 and αEPCR-4 BMDMs) versus HG-NG-aPC (d, right panel) BMDMs. One-way ANOVA with Bonferroni-adjusted post hoc comparison of WT (HG and HG-NG versus NG and HG-NG-aPC versus HG-NG) and HG-NG-aPC (PAR3−/− and PAR2−/− BMDMs) versus HG-NG-aPC (PAR1−/− BMDMs) (d, left panel). Uncropped immunoblots for Fig. 6a–d are provided in Supplementary Figure 20 and Supplementary Figure 21, respectivelyCC BY · PubMed Central
Fig. 7 aPC reverses the glucose-induced and sustained pro-atherogenic phenotype of macrophages. a, b Representative co-immunofluorescence images (a, left panel) for 8-Oxo-dG (green; DAPI nuclear counterstain, blue) and immunoblots images (out of three independent repeat experiments with two technical replicates each) for nitrotyrosine (Nitro, b, top; GAPDH: loading control) of BMDMs with treatment as indicated and dot plot summarizing data (a, right panel, b, bottom). c Representative reverse-transcriptase-PCR gel images (out of three independent repeat experiments with two technical replicates each) for IL-6 and TNF-α (right panel; β-actin: loading control) and dot plot summarizing data (middle and right panels, respectively). d Representative immunoblot images (out of four independent repeat experiments with two technical replicates each) for NF-κB p65 (top panel; GAPDH: loading control) and dot plot summarizing data (bottom). e Representative Oil Red O images reflecting lipid uptake into BMDMs (left panel) and dot plot summarizing data (right panel). NG: normal glucose (5 mM glucose plus 20 mM mannitol, 48 h), HG: high glucose (25 mM, 48 h), HG-NG: HG (48 h) followed by NG (24 h) condition; HG-NG-aPC: HG-NG conditions with additional exposure to aPC (20 nM) during the last 24 h). Data shown as dot plots represent mean ± SEM of at least three independent repeat experiments with at least two technical replicates each; **P < 0.01 (one-way ANOVA with Bonferroni-adjusted post hoc comparison of HG and HG-NG versus NG and HG-NG-aPC versus HG-NG). Uncropped immunoblots for Fig. 7b, d and reverse-transcriptase-PCR gel images for Fig. 7c are provided in Supplementary Figure 22
Fig. 7 aPC reverses the glucose-induced and sustained pro-atherogenic phenotype of macrophages. a, b Representative co-immunofluorescence images (a, left panel) for 8-Oxo-dG (green; DAPI nuclear counterstain, blue) and immunoblots images (out of three independent repeat experiments with two technical replicates each) for nitrotyrosine (Nitro, b, top; GAPDH: loading control) of BMDMs with treatment as indicated and dot plot summarizing data (a, right panel, b, bottom). c Representative reverse-transcriptase-PCR gel images (out of three independent repeat experiments with two technical replicates each) for IL-6 and TNF-α (right panel; β-actin: loading control) and dot plot summarizing data (middle and right panels, respectively). d Representative immunoblot images (out of four independent repeat experiments with two technical replicates each) for NF-κB p65 (top panel; GAPDH: loading control) and dot plot summarizing data (bottom). e Representative Oil Red O images reflecting lipid uptake into BMDMs (left panel) and dot plot summarizing data (right panel). NG: normal glucose (5 mM glucose plus 20 mM mannitol, 48 h), HG: high glucose (25 mM, 48 h), HG-NG: HG (48 h) followed by NG (24 h) condition; HG-NG-aPC: HG-NG conditions with additional exposure to aPC (20 nM) during the last 24 h). Data shown as dot plots represent mean ± SEM of at least three independent repeat experiments with at least two technical replicates each; **P < 0.01 (one-way ANOVA with Bonferroni-adjusted post hoc comparison of HG and HG-NG versus NG and HG-NG-aPC versus HG-NG). Uncropped immunoblots for Fig. 7b, d and reverse-transcriptase-PCR gel images for Fig. 7c are provided in Supplementary Figure 22CC BY · PubMed Central
Fig. 8 aPC epigenetically inhibits glucose-induced sustained p66Shc expression. a Representative reverse-transcriptase-PCR gel images (out of three independent repeat experiments, top) showing methylated (M) and unmethylated (U) p66Shc promoter DNA in BMDMs with treatment as indicated and dot plot summarizing the ratio of methylated to unmethylated p66Shc promoter DNA (bottom). b Glucose-induced sustained p66Shc mRNA expression is prevented by aPC (20 nM) in BMDMs cells. Representative RT-PCR gel image (out of five independent repeat experiments, top; β-actin: loading control) and dot plot summarizing data (bottom). c Representative immunoblot images (out of 3 independent repeat experiments with two technical replicates each) for p66Shc and DNMT1 expression in BMDMs with treatment as indicated (left panel; GAPDH: loading control) and dot plot summarizing data (middle and right panels). d dot plot summarizing DNMT activity in BMDMs with treatment as indicated. NG: normal glucose (5 mM glucose plus 20 mM mannitol, 48 h), HG: high glucose (25 mM, 48 h). HG-NG: HG (24 h) followed by NG (24 h) condition; HG-NG-aPC: HG-NG conditions with additional exposure to aPC (20 nM) during the last 24 h); HG-NG-Aza: HG-NG conditions with additional exposure to the DNMT-inhibitor 5-azacytidine (Aza, 5 µM) during the last 24 h; HG-NG-aPC-Aza: HG-NG conditions with additional and concomitant exposure to aPC (20 nM) and 5-azacytidine (5 µM) during the last 24 h. Data shown represent mean ± SEM of at least three independent experiments each with at least two technical replicates (a–d); **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of HG and HG-NG versus NG, HG-NG-aPC versus HG-NG (a, b, d), and HG-NG, HG-NG-Aza, HG-NG-aPC-Aza versus DM-NG-aPC). Uncropped reverse-transcriptase-PCR gel images for Fig. 8a, b and immunoblots for Fig. 8c are provided in Supplementary Figure 23
Fig. 8 aPC epigenetically inhibits glucose-induced sustained p66Shc expression. a Representative reverse-transcriptase-PCR gel images (out of three independent repeat experiments, top) showing methylated (M) and unmethylated (U) p66Shc promoter DNA in BMDMs with treatment as indicated and dot plot summarizing the ratio of methylated to unmethylated p66Shc promoter DNA (bottom). b Glucose-induced sustained p66Shc mRNA expression is prevented by aPC (20 nM) in BMDMs cells. Representative RT-PCR gel image (out of five independent repeat experiments, top; β-actin: loading control) and dot plot summarizing data (bottom). c Representative immunoblot images (out of 3 independent repeat experiments with two technical replicates each) for p66Shc and DNMT1 expression in BMDMs with treatment as indicated (left panel; GAPDH: loading control) and dot plot summarizing data (middle and right panels). d dot plot summarizing DNMT activity in BMDMs with treatment as indicated. NG: normal glucose (5 mM glucose plus 20 mM mannitol, 48 h), HG: high glucose (25 mM, 48 h). HG-NG: HG (24 h) followed by NG (24 h) condition; HG-NG-aPC: HG-NG conditions with additional exposure to aPC (20 nM) during the last 24 h); HG-NG-Aza: HG-NG conditions with additional exposure to the DNMT-inhibitor 5-azacytidine (Aza, 5 µM) during the last 24 h; HG-NG-aPC-Aza: HG-NG conditions with additional and concomitant exposure to aPC (20 nM) and 5-azacytidine (5 µM) during the last 24 h. Data shown represent mean ± SEM of at least three independent experiments each with at least two technical replicates (a–d); **P < 0.01; one-way ANOVA with Bonferroni-adjusted post hoc comparison of HG and HG-NG versus NG, HG-NG-aPC versus HG-NG (a, b, d), and HG-NG, HG-NG-Aza, HG-NG-aPC-Aza versus DM-NG-aPC). Uncropped reverse-transcriptase-PCR gel images for Fig. 8a, b and immunoblots for Fig. 8c are provided in Supplementary Figure 23CC BY · PubMed Central
Fig. 9 aPC reverses hyperglycaemic induced and epigenetically sustained p66Shc expression, promoting atherosclerotic plaque regression in mice. a Experimental design (left top) and representative Oil Red O-stained images of aortic roots (left bottom) and dot plot summarizing data (right). b, c Representative co-immunofluorescence images for p66Shc (b, red), 8-Oxo-dG (c, red), macrophages (MOMA-2, b, c, green), and DAPI nuclear counterstain (b, c, blue; boxed areas shown at higher magnification in the lower panel). Dot plot summarize data for p66Shc-MOMA-2 (b) and 8-Oxo-dG-MOMA-2 co-localization (c, both Icorr, correlation index). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM: hyperglycaemic ApoE−/− mice; DM-NG-PBS: ApoE−/− DM mice receiving the SGLT2 inhibitor and PBS from week 16 to week 22; DM-NG-aPC: ApoE−/− DM mice with concomitant SGLT2 inhibitor and aPC treatment from week 16 to week 22; DM-NG-aPC-Aza: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and 5-azacytidine. Data shown as dot plots represent mean ± SEM of 8–10 mice per group (a, c); size bars: a–c: 20 µm; **P < 0.01 (one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM and DM-NG-aPC versus control and DM-NG-PBS and DM-NG-aPC-Aza versus DM-NG-aPC)
Fig. 9 aPC reverses hyperglycaemic induced and epigenetically sustained p66Shc expression, promoting atherosclerotic plaque regression in mice. a Experimental design (left top) and representative Oil Red O-stained images of aortic roots (left bottom) and dot plot summarizing data (right). b, c Representative co-immunofluorescence images for p66Shc (b, red), 8-Oxo-dG (c, red), macrophages (MOMA-2, b, c, green), and DAPI nuclear counterstain (b, c, blue; boxed areas shown at higher magnification in the lower panel). Dot plot summarize data for p66Shc-MOMA-2 (b) and 8-Oxo-dG-MOMA-2 co-localization (c, both Icorr, correlation index). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM: hyperglycaemic ApoE−/− mice; DM-NG-PBS: ApoE−/− DM mice receiving the SGLT2 inhibitor and PBS from week 16 to week 22; DM-NG-aPC: ApoE−/− DM mice with concomitant SGLT2 inhibitor and aPC treatment from week 16 to week 22; DM-NG-aPC-Aza: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and 5-azacytidine. Data shown as dot plots represent mean ± SEM of 8–10 mice per group (a, c); size bars: a–c: 20 µm; **P < 0.01 (one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM and DM-NG-aPC versus control and DM-NG-PBS and DM-NG-aPC-Aza versus DM-NG-aPC)CC BY · PubMed Central
Fig. 10 aPC-mediated reversal of hyperglycaemia-induced persistent p66Shc expression and plaque instability depends on DNMT1. a Experimental design. b Representative images of Oil Red O-stained aortic root lesions (left panel) and dot plot summarizing data (right panel). c Dot plots summarizing morphometric analyses of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d Representative images showing immunofluorescence staining of macrophages within lesions (MOMA-2, green; DAPI nuclear counterstain, blue; left panel) and dot plot summarizing data (right panel). e Representative co-immunofluorescence images for 8-Oxo-dG (red), macrophages (MOMA-2, green), and DAPI nuclear counterstain (blue) within aortic root lesions (left, ×10 magnified images shown in lower panel) and dot plot summarizing data (Icorr, correlation index, right). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM-NG: ApoE−/− DM mice receiving the SGLT2 inhibitor and PBS from week 16 to week 22; DM-NG-aPC-DNMT1-MO: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and DNMT1-MO treatment; DM-NG-aPC-Cont-MO: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and control morpholino treatment. Data shown as dot plots represent mean ± SEM of 8–10 mice per group; size bars: b, d, e 20 µm; **P < 0.01; b–e one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM-NG and DM-NG-aPC-DNMT1-MO versus DM-NG-aPC-Cont-MO)
Fig. 10 aPC-mediated reversal of hyperglycaemia-induced persistent p66Shc expression and plaque instability depends on DNMT1. a Experimental design. b Representative images of Oil Red O-stained aortic root lesions (left panel) and dot plot summarizing data (right panel). c Dot plots summarizing morphometric analyses of necrotic core area (left panel), fibrous cap thickness (middle panel), and frequency of ruptured shoulders (right panel). d Representative images showing immunofluorescence staining of macrophages within lesions (MOMA-2, green; DAPI nuclear counterstain, blue; left panel) and dot plot summarizing data (right panel). e Representative co-immunofluorescence images for 8-Oxo-dG (red), macrophages (MOMA-2, green), and DAPI nuclear counterstain (blue) within aortic root lesions (left, ×10 magnified images shown in lower panel) and dot plot summarizing data (Icorr, correlation index, right). Cont: normoglycaemic ApoE−/− mice with normal chow diet; DM-NG: ApoE−/− DM mice receiving the SGLT2 inhibitor and PBS from week 16 to week 22; DM-NG-aPC-DNMT1-MO: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and DNMT1-MO treatment; DM-NG-aPC-Cont-MO: DM-NG mice with concomitant SGLT2 inhibitor, aPC, and control morpholino treatment. Data shown as dot plots represent mean ± SEM of 8–10 mice per group; size bars: b, d, e 20 µm; **P < 0.01; b–e one-way ANOVA with Bonferroni-adjusted post hoc comparison of DM-NG and DM-NG-aPC-DNMT1-MO versus DM-NG-aPC-Cont-MO)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 40

Metadata

Authors
Shahzad, K., Gadi, I., Nazir, S., Al-Dabet, M. M., Kohli, S., Bock, F., Breitenstein, L., Ranjan, S., Fuchs, T., Halloul, Z., Nawroth, P. P., Pelicci, P. G., Braun-Dullaeus, R. C., Camerer, E., Esmon, C. T., & Isermann, B.
Affiliations
  • University of Sargodha (PK)
  • Otto-von-Guericke-Universität Magdeburg (DE)
  • Vanderbilt University Medical Center (US)
  • Heidelberg University (DE)
  • European Institute of Oncology (IT)
  • Inserm (FR)
  • Oklahoma Medical Research Foundation (US)
Corresponding author
  • Shahzad, Khurrum
  • Isermann, Berend
Venue
Communications Biology
Published
2018-08-06
Volume
1
Issue
1
Pages
104-104
ISSN
2399-3642 (ISSN-L)
OpenAlex
W2885767674
Cited by
40
References
68
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 5
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Deutscher Akademischer Austauschdienst
  • Deutsche Forschungsgemeinschaft (RTG2408/P7&amp, (IS-67/8-1, KO5736-/1-1, IS-67/5-3, CRC) 1118, CRC854/B26, SFB1118, RTG2408/P5, IS-67/11-1, RTG2408, CRC854, RTG2408/P7, SH849/1-2, RTG2408/P7&amp;P9)
  • National Heart, Lung, and Blood Institute (UM1HL120877)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
activated protein C, p66Shc, diabetic atherosclerosis, reactive oxygen species, CpG hypomethylation, DNA methylation, DNMT1, protease-activated receptor 1, epigenetic regulation, hyperglycemia, atherosclerotic plaque

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes. https://app.cochat.ai/papers/10.1038/s42003-018-0108-5
The paper
Shahzad, K., Gadi, I., Nazir, S., Al-Dabet, M. M., Kohli, S., Bock, F., Breitenstein, L., Ranjan, S., Fuchs, T., Halloul, Z., Nawroth, P. P., Pelicci, P. G., Braun-Dullaeus, R. C., Camerer, E., Esmon, C. T., & Isermann, B. (2018). Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes. Communications Biology. https://doi.org/10.1038/s42003-018-0108-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.